UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 83

Sortiert nach

A Feedback Loop Between the Liver-Enriched Transcription Factor Network and Mir-122 Controls Hepatocyte Differentiation

Gastroenterology (New York, N.Y. 1943), 2012, Vol.142 (1), p.119-129

2012

Link zum Volltext

Verfügbarkeit prüfen

Barriers to end-of-life discussions among hematologists: A qualitative study

Palliative medicine, 2018-05, Vol.32 (5), p.1021-1029

2018

Link zum Volltext

Verfügbarkeit prüfen

Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts

Blood, 2014-03, Vol.123 (12), p.1833-1835

2014

Link zum Volltext

Verfügbarkeit prüfen

Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia

The Journal of experimental medicine, 2008-04, Vol.205 (4), p.751-758

2008

Link zum Volltext

Verfügbarkeit prüfen

Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors

Blood, 2014-12, Vol.124 (26), p.3924-3931

2014

Link zum Volltext

Verfügbarkeit prüfen

Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors

Haematologica (Roma), 2011-06, Vol.96 (6), p.845-853

2011

Link zum Volltext

Verfügbarkeit prüfen

Gene-Expression and Immunohistochemical Study of Specific T-Cell Subsets and Accessory Cell Types in the Transformation and Prognosis of Follicular Lymphoma

Journal of clinical oncology, 2007-02, Vol.25 (4), p.390-398

2007

Link zum Volltext

Verfügbarkeit prüfen

The clinical relevance of imatinib plasma trough concentrations in chronic myeloid leukemia. A Belgian study

Clinical biochemistry, 2017-05, Vol.50 (7-8), p.452-454

2017

Link zum Volltext

Verfügbarkeit prüfen

Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes

Blood, 2012-05, Vol.119 (20), p.4625-4635

2012

Link zum Volltext

Verfügbarkeit prüfen

Comparison of stable human Treg and Th clones by transcriptional profiling

European journal of immunology, 2009-03, Vol.39 (3), p.869-882

2009

Link zum Volltext

Verfügbarkeit prüfen

ETV6-PDGFRB and FIP1L1-PDGFRA stimulate human hematopoietic progenitor cell proliferation and differentiation into eosinophils: the role of nuclear factor-κB

Haematologica (Roma), 2012-07, Vol.97 (7), p.1064-1072

2012

Link zum Volltext

Verfügbarkeit prüfen

IL-9 and its Receptor: From Signal Transduction to Tumorigenesis

Growth factors (Chur, Switzerland), 2004-12, Vol.22 (4), p.207-215

2004

Link zum Volltext

Verfügbarkeit prüfen

The role of the p53 pathway in the treatment of follicular lymphoma

Cell cycle (Georgetown, Tex.), 2008-02, Vol.7 (4), p.436-439

2008

Link zum Volltext

Verfügbarkeit prüfen

In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma

Blood, 2007-08, Vol.110 (4), p.1116-1122

2007

Link zum Volltext

Verfügbarkeit prüfen

ALL-associated JAK1 mutations confer hypersensitivity to the antiproliferative effect of type I interferon

Blood, 2010-04, Vol.115 (16), p.3287-3295

2010

Link zum Volltext

Verfügbarkeit prüfen

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

The New England journal of medicine, 2012-03, Vol.366 (9), p.787-798

2012

Link zum Volltext

Verfügbarkeit prüfen

Escalation of Commitment in Treatment Decisions Near the End of Life

JAMA oncology, 2017-09, Vol.3 (9), p.1174

2017

Link zum Volltext

Verfügbarkeit prüfen

B Lymphocytes Are Critical for Lung Fibrosis Control and Prostaglandin E2 Regulation in IL-9 Transgenic Mice

American journal of respiratory cell and molecular biology, 2006-05, Vol.34 (5), p.573-580

2006

Link zum Volltext

Verfügbarkeit prüfen

JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications

Haematologica (Roma), 2015-10, Vol.100 (10), p.1240-1253

2015

Link zum Volltext

Verfügbarkeit prüfen

Transcription factor regulation can be accurately predicted from the presence of target gene signatures in microarray gene expression data

Nucleic acids research, 2010-06, Vol.38 (11), p.e120

2010

Link zum Volltext

Verfügbarkeit prüfen

miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets

Blood, 2010-07, Vol.116 (3), p.437-445

2010

Link zum Volltext

Verfügbarkeit prüfen

Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities

The Journal of biological chemistry, 2015-11, Vol.290 (48), p.29022-29034

2015

Link zum Volltext

Verfügbarkeit prüfen

A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma

Haematologica (Roma), 2018-05, Vol.103 (5), p.840-848

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 83

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(80)
Mit Volltextzugriff
(78)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(44)
Science & Technology
(44)
Humans
(38)
Hematology
(23)
Female
(21)
Male
(19)
Biological And Medical Sciences
(17)
Middle Aged
(17)
Animals
(16)
Medical Sciences
(16)
Aged
(15)
Hematologic And Hematopoietic Diseases
(15)
Mice
(14)
Adult
(12)
Aged, 80 And Over
(12)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(12)
Cell Biology
(9)
Immunology
(9)
Janus Kinase 1 - Genetics
(9)
Mutation
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A Feedback Loop Between the Liver-Enriched Transcription Factor Network and Mir-122 Controls Hepatocyte Differentiation

Barriers to end-of-life discussions among hematologists: A qualitative study

Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts

Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia

Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors

Oncogenic JAK1 and JAK2-activating mutations resistant to ATP-competitive inhibitors

Gene-Expression and Immunohistochemical Study of Specific T-Cell Subsets and Accessory Cell Types in the Transformation and Prognosis of Follicular Lymphoma

The clinical relevance of imatinib plasma trough concentrations in chronic myeloid leukemia. A Belgian study

Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomes

Comparison of stable human Treg and Th clones by transcriptional profiling

ETV6-PDGFRB and FIP1L1-PDGFRA stimulate human hematopoietic progenitor cell proliferation and differentiation into eosinophils: the role of nuclear factor-κB

IL-9 and its Receptor: From Signal Transduction to Tumorigenesis

The role of the p53 pathway in the treatment of follicular lymphoma

In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma

ALL-associated JAK1 mutations confer hypersensitivity to the antiproliferative effect of type I interferon

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

Escalation of Commitment in Treatment Decisions Near the End of Life

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

B Lymphocytes Are Critical for Lung Fibrosis Control and Prostaglandin E2 Regulation in IL-9 Transgenic Mice

JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications

Transcription factor regulation can be accurately predicted from the presence of target gene signatures in microarray gene expression data

miR-28 is a thrombopoietin receptor targeting microRNA detected in a fraction of myeloproliferative neoplasm patient platelets

Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) study

Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities

A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma

Suchergebnisse filtern